Justin Klein and Kirk Nielsen entered venture capital separately 13 years ago, taking roles at two of the top firms in Medtech. Over that time, the two VCs have led investment in more than a dozen Medtech companies that have either gone public or been acquired. Now, the pair have joined forces to create Vensana Capital, a new investor in Medtech. In this episode, you’ll hear why they decided to venture out on their own and where they’ll be investing $225 million in capital from their first fund.
Justin Klein, MD, JD
Managing Partners
Vensana Capital
Justin Klein, MD, JD is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin was previously a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently or previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical, and VytronUS. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.
